AQST

Aquestive Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 0/10
  • Value↓ 0/10
Aquestive Therapeutics sales and earnings growth
AQST Growth
Low
  • Revenue Y/Y↓ -24.90%
  • EPS Y/Y↓ -5.08%
  • FCF Y/Y↑ 9.63%
Aquestive Therapeutics gross and profit margin trends
AQST Profitability
Fair
  • Gross margin ↑ 63.50%
  • EPS margin↓ -137.10%
  • ROIC 5Y↓ -22.46%
Aquestive Therapeutics net debt vs free cash flow
AQST Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.5
  • Interest coverage↓ -3.1

Aquestive Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Drug Manufacturers - Specialty & Generic stocks